-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion

PUBT·04/27/2026 12:44:58
Listen to the news
BioMarin completes Amicus acquisition for USD 14.5 per share, valuing deal at USD 4.8 billion
  • BioMarin completed acquisition of Amicus Therapeutics in an all-cash deal priced at USD 14.5 per share.
  • Total equity value of transaction was about USD 4.8 billion.
  • Deal adds Fabry disease drug Galafold to BioMarin commercial portfolio.
  • Transaction also brings Pompe disease therapy Pombiliti with Opfolda.
  • BioMarin expects to provide updated FY 2026 guidance during first-quarter earnings call on May 4, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604270844PR_NEWS_USPR_____SF43684) on April 27, 2026, and is solely responsible for the information contained therein.